Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:50:44.195Z.
Consensus retrieved: 2026-10-06T08:40:54.579Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:50:44.195Z.
Quote observation: 2026-10-06T14:50:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 99964f13ae30c95c0b3a7ffda2d7021ed4a1e29c98fea0dced007a9b6e24aa9f
Forward PE Ratio (N/A) = Dated Quote Price ($41.41) / Consensus Forward EPS ($-0.53)
FORWARD PE RATIO
N/A
Alkermes plc
Market Cap
$6.95B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Alkermes plc (ALKS) | $6.95B | N/A |
| Chemed Corporation (CHE)vs › | $6.67B | 20.03 |
| Immunovant, Inc. (IMVT)vs › | $6.63B | N/A |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.29B | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.60B | N/A |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 18.53 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.42B | 19.63 |
| Hinge Health, Inc. (HNGE)vs › | $7.51B | 41.87 |
| HealthEquity, Inc. (HQY)vs › | $7.59B | 19.22 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.66B | N/A |
Trailing P/E
108.1
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $41.41, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.53 | $-0.67 – $-0.31 | 9 | n/m |
| 2027-12-31 | $0.53 | $-1.91 – $3.11 | 8 | 77.6x |
| 2028-12-31 | $1.14 | $-0.24 – $3.47 | 11 | 36.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
